Sumitomo Dainippon Pharma Co Ltd's Fiscal Year is From April To March.
The item "Enterprise-Value-To-Sales-Ratio" stands at 1.39 as of 09/30/2025.
As of the end of Sumitomo Dainippon Pharma Co Ltd's second quarter, the item "Enterprise Value To Sales Ratio" stands at 1.39. This represents an increase of 37.69 percent compared to it's value at the end of it's first quarter .
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -7.56 percent compared to the value the year prior.
The 1 year change in percent is -7.56.
The 3 year change in percent is 114.83.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Enterprise Value To Sales Ratio | 905,699,262,464.00 |
![]() | Johnson & Johnson - Enterprise Value To Sales Ratio | 486,508,953,600.00 |
![]() | AbbVie Inc - Enterprise Value To Sales Ratio | 399,570,305,024.00 |
![]() | Roche Holding AG - Enterprise Value To Sales Ratio | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Enterprise Value To Sales Ratio | 280,205,508,085.11 |